Replies to post #81639 on Biotech Values

[dewophile]

RIGL

"Note that RIGL's R788 showed better efficacy results in a similar trial (methotrexate failures studied for 6 months of treatment). See: http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=1305912&highlight=

In particular, R788 had an ACR20 response rate of 66% (p<0.001) at the 100mg bid dose "

I don't think you can make this case because the placebo-adjusted RR is about the same